Medtronic plc , a global leader in healthcare technology, has appointed John Groetelaars and Bill Jellison as independent directors, effective immediately.
In line with its commitment to enhancing shareholder value, the company’s Board of Directors has also created two new committees:
The Growth Committee – to oversee tuck-in M&A, organic R&D investments, potential divestitures, and the separation of the Diabetes business.
The Operating Committee – to support initiatives focused on operational performance, margin expansion, and global manufacturing and supply chain efficiency.
Geoff Martha, Medtronic’s Chairman and CEO, will chair both committees, with Groetelaars and Jellison also serving as members. Martha emphasized that their extensive leadership and financial expertise will strengthen Medtronic’s strategic focus, particularly as it advances portfolio optimization and prepares for the separation of MiniMed.
Medtronic will further detail the committees’ work and long-term strategy at its Investor Day in mid-2026. These initiatives follow constructive discussions with Elliott Investment Management, one of the company’s largest investors. Both Martha and Elliott’s Marc Steinberg highlighted the company’s strong momentum, driven by breakthrough therapies, portfolio simplification, and operational improvements, positioning Medtronic for sustainable growth and higher shareholder returns.
Groetelaars and Jellison will stand for election at Medtronic’s 2025 Annual General Meeting of Shareholders.